scholarly journals Modern considerations on the predisposing factors in the etiopathogenesis of systemic lupus erythematosus

2021 ◽  
Vol 68 (1) ◽  
pp. 22-30
Author(s):  
Ionica-Mariana Radulescu ◽  
◽  
Mihail Alecu ◽  
Laura Ion ◽  
Cosmin Moldovan ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Clinical Signs ◽  
Clinical Manifestations ◽  
Published Data ◽  
Women Of Childbearing Age ◽  
Childbearing Age ◽  
Systemic Lupus ◽  
Trigger Factors

Lupus erythematosus is an autoimmune disease with severe skin involvement and/or multisystemic implications characterized by the development of autoantibodies and immune complexes that, in turn, cause inflammation, tissue damage and a variety of clinical manifestations. The etiopathogeny of lupus erythematosus is very complex and still incompletely discovered. The onset of this disease or the episodes of exacerbation involves various factors: genetic, immune, hormonal, environmental but many more are still under research. There is strong evidence to back up the theory of an autoimmune disease, even though the precise mechanism is yet to be discovered. Apart from a preexisting background predisposing to lupus, certain triggers are required to act in a synergic way to determine the onset of the clinical signs. Studies show that it is 10-15 times more common in women of childbearing age than men, with a higher incidence amongst Afro-American population compared to Caucasians. The aim of this article is to shed some light on the most important determining and trigger factors involved in systemic lupus erythematosus by reviewing the most recent published data.

Multisystem diseases

2012 ◽  
Author(s):  
James Carton
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Women Of Childbearing Age ◽  
Childbearing Age ◽  
Systemic Lupus ◽  
Autoantibody Production

Systemic lupus erythematosus 346Systemic sclerosis 348Sarcoidosis 349Vasculitis 350• A multisystem autoimmune disease characterized by autoantibody production against a number of nuclear and cytoplasmic autoantigens.• Incidence of 4 per 100,000 people per year.• Most cases occur in women of childbearing age....

scholarly journals Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study

Lupus ◽  
2021 ◽  
pp. 096120332098484
Author(s):  
Min Kyung Chung ◽  
Jin Su Park ◽  
Hyunsun Lim ◽  
Chan Hee Lee ◽  
Jisoo Lee
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Health Information ◽  
National Health ◽  
Lupus Erythematosus ◽  
Health Resources ◽  
Population Group ◽  
Korean Women ◽  
Women Of Childbearing Age ◽  
Childbearing Age ◽  
Systemic Lupus

Background Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive years, but the incidence and prevalence of SLE among women of childbearing age have not been studied. The objective of this study was to estimate the incidence and prevalence of SLE among the Korean women of childbearing age. Methods Women aged 20 to 44 years with SLE were identified from National Health Insurance Service – National Health Information Database (2009-2016), which contain health information of approximately 97% of the Korean population. SLE was defined by International Classification of Diseases, 10th revision code, M32. Incidence and prevalence were calculated per 100,000 person-years and stratified by year and age. Results A total of 12,756 women with SLE were identified. The incidence of SLE from 2011 to 2016 among women in childbearing years was 8.18/100,000 person-years (95% CI 7.94–8.43), with the highest incidence in 2016 (8.56/100,000 person-years, 95% CI 7.95–9.17) and the lowest incidence in 2012 (7.85/100,000 person-years, 95% CI 7.28–8.42). The prevalence of SLE from 2009 to 2016 among women in childbearing years was 77.07/100,000 person-years (95% CI 75.76–78.39), with the highest prevalence in 2014 (79.47/100,000 person-years, 95% CI 77.64–81.30) and the lowest in 2010 (74.19/100,000 person-years, 95% CI 72.45–75.93). The peak age for SLE incidence was between 25–39 years, and lower incidence was seen in the early (20–24 years) and late (40–44 years) childbearing age periods. There was an increasing trend in prevalence according to age in women of childbearing age, with the highest prevalence occurring in the 40–44 age group. Conclusions The risk and burden of SLE are high among women during their childbearing years. This calls for special attention to this particular population group when allocating health resources.

Systemic lupus erythematosus—clinical features and aetiopathogenesis

2013 ◽  
pp. 923-937
Author(s):  
Caroline Gordon
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Differential Diagnosis ◽  
Autoimmune Disease ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Immune Complexes ◽  
Clinical Manifestations ◽  
Systemic Lupus ◽  
Life Threatening ◽  
Symptoms And Signs

Systemic lupus erythematosus (SLE or lupus) is a multisystem, autoimmune disease associated with the formation of autoantibodies that form pathological immune complexes and activate a number of inflammatory pathways. The disease is characterized by remissions and relapses (flares) that can present with a variety of clinical manifestations. The symptoms and signs may range from mild features that can be treated easily to organ and even life threatening manifestations requiring potent immunosuppression. This chapter will review the epidemiology and pathology of lupus, then the clinical features including differential diagnosis and investigation of adult patients with SLE. Finally the classification, diagnosis, monitoring and outcome of lupus patients will be discussed.

scholarly journals Recent advances in the management of systemic lupus erythematosus

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 970 ◽  
Author(s):  
Savino Sciascia ◽  
Massimo Radin ◽  
Dario Roccatello ◽  
Giovanni Sanna ◽  
Maria Laura Bertolaccini
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Side Effects ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Therapeutic Strategies ◽  
Systemic Lupus ◽  
Systemic Involvement ◽  
Phase Ii And Iii ◽  
Chronic Autoimmune Disease

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease presenting highly heterogeneous clinical manifestations and multi-systemic involvement. Patients are susceptible to relapse­ and remission, thus making management challenging. Moreover, a considerable number of side effects may occur with conventional therapies; therefore, there is clearly a need for new therapeutic strategies. Since the pathogenesis of SLE is highly complex, it is far from being fully understood. However, greater understanding of the pathways and of the cellular and molecular mediators involved in SLE is being achieved. Emerging evidence has allowed the development of new biological therapeutic options targeting crucial molecular mediators involved in the pathogenesis of SLE. This literature review analyzes the availability of biological and target-directed treatments, phase II and III trials, and new therapies that are being developed for the treatment of SLE.

Lupus Nephritis diagnosed by stand-alone renal histopathological findings in a middle-aged male.

JMS SKIMS ◽  
2020 ◽  
Vol 23 (1) ◽  
pp. 41-44
Author(s):  
Rayees Yousuf Sheikh ◽  
Nucksheeba Aziz Bhat ◽  
Rajat Mangal ◽  
Alok Sharma
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
High Sensitivity ◽  
Women Of Childbearing Age ◽  
Childbearing Age ◽  
Systemic Lupus ◽  
Histopathological Findings ◽  
Nuclear Antigens ◽  
Autoimmune Condition

Systemic lupus erythematosus (SLE) is a systemic autoimmune condition, characterized by the production of autoantibodies, predominantly against nuclear antigens. It primarily affects women of childbearing age. Men account for 4-22% of all cases in various series (1,2). Lupus nephritis can be diagnosed with high sensitivity and specificity based on histopathological criteria alone (3). We report lupus nephritis in a 50-year-old male diagnosed solely on renal histopathological findings.

scholarly journals Increased CD21-CD27- atypical memory B cells as a biomarker of clinical disease activity in patients with systemic lupus erythematosus

2021 ◽  
Author(s):  
Alice Horisberger ◽  
Morgane Humbel ◽  
Natalia Fluder ◽  
Florence Bellanger ◽  
Craig Fenwick ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
B Cells ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Clinical Signs ◽  
Clinical Manifestations ◽  
Memory B Cells ◽  
Clinical Disease ◽  
Systemic Lupus ◽  
Clinical Disease Activity

Abstract Background Determining disease activity in systemic lupus erythematosus (SLE) patients is challenging and limited by the lack of reliable biomarkers. Analysis of the altered distribution of circulating B cells has shown promise for assessment disease activity. Yet studies are limited by variable classifications of B subsets. Therefore, we studied peripheral B cells using high-dimensional tools to identify a valid biomarker of disease activity.Methods We studied B cells in two separate cohorts of patients included in the Swiss SLE Cohort Study. In discovery cohort A, we analyzed cryopreserved PBMCs from 30 SLE, and 30 age-, sex- and ethnicity matched healthy controls (HC) by mass cytometry. In validation cohort B, fresh blood from 63 SLE, 14 Sjögren syndrome (pSS), 14 Sarcoidosis (Sarc), and 39 age-matched HC were analyzed by flow cytometry.Results In cohort A, using unsupervised clustering analysis, we identified 7 metaclusters within B cells. Two metaclusters were increased in SLE and exhibited a phenotype of atypical memory B cells (aMBC): CD21-, CD27-, CD11c+ and CXCR5-. Based on cohort A results, we confirmed in cohort B the increase in CD21-CD27- aMBC in SLE, compared to healthy and disease controls. In both cohorts, aMBC were associated with the severity of clinical manifestations. Compared to classical biomarkers, aMBC showed a significant correlation with clinical signs of disease activity. Conclusion aMBC were expanded in SLE, and the increase correlated with clinical disease activity. According to our data, aMBC represents a robust and easily accessible biomarker to assess disease activity in patients with SLE.

Systemic lupus erythematosus—clinical features and aetiopathogenesis

2013 ◽  
Author(s):  
Caroline Gordon
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Differential Diagnosis ◽  
Autoimmune Disease ◽  
Clinical Features ◽  
Lupus Erythematosus ◽  
Immune Complexes ◽  
Clinical Manifestations ◽  
Systemic Lupus ◽  
Life Threatening ◽  
Symptoms And Signs

Systemic lupus erythematosus (SLE or lupus) is a multisystem, autoimmune disease associated with the formation of autoantibodies that form pathological immune complexes and activate a number of inflammatory pathways. The disease is characterized by remissions and relapses (flares) that can present with a variety of clinical manifestations. The symptoms and signs may range from mild features that can be treated easily to organ and even life threatening manifestations requiring potent immunosuppression. This chapter will review the epidemiology and pathology of lupus, then the clinical features including differential diagnosis and investigation of adult patients with SLE. Finally the classification, diagnosis, monitoring and outcome of lupus patients will be discussed.

scholarly journals Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: a nationwide population-based study

2020 ◽  
Author(s):  
Min Kyung Chung ◽  
Jin Su Park ◽  
Hyun Sun Lim ◽  
Chan Hee Lee ◽  
Jisoo Lee
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Health Information ◽  
National Health ◽  
Lupus Erythematosus ◽  
Health Resources ◽  
Population Group ◽  
Korean Women ◽  
Women Of Childbearing Age ◽  
Childbearing Age ◽  
Systemic Lupus

Abstract Background Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive years, but the incidence and prevalence of SLE among women of childbearing age have not been studied. The objective of this study was to estimate the incidence and prevalence of SLE among the Korean women of childbearing age. Methods Women aged 20 to 44 years with SLE were identified from National Health Insurance Service – National Health Information Database (2009–2016), which contain health information of approximately 97% of the Korean population. SLE was defined by International Classification of Diseases, 10th revision code, M32. Incidence and prevalence were calculated per 100,000 person-years and stratified by year and age. Results A total of 12,756 women with SLE were identified. The incidence of SLE from 2011 to 2016 among women in childbearing years was 8.18/100,000 person-years (95% CI 7.94–8.43), with the highest incidence in 2016 (8.56/100,000 person-years, 95% CI 7.95–9.17) and the lowest incidence in 2012 (7.85/100,000 person-years, 95% CI 7.28–8.42). The prevalence of SLE from 2009 to 2016 among women in childbearing years was 77.07/100,000 person-years (95% CI 75.76–78.39), with the highest prevalence in 2014 (79.47/100,000 person-years, 95% CI 77.64–81.30) and the lowest in 2010 (74.19/100,000 person-years, 95% CI 72.45–75.93). The peak age for SLE incidence was between 25–39 years, and lower incidence was seen in the early (20–24 years) and late (40–44 years) childbearing age periods. There was an increasing trend in prevalence according to age in women of childbearing age, with the highest prevalence occurring in the 40–44 age group. Conclusions The risk and burden of SLE are high among women during their childbearing years. This calls for special attention to this particular population group when allocating health resources.

Clinical case of lung lesions in patient with newly diagnosed systemic lupus erythematosus

2019 ◽  
Vol 1 (9) ◽  
pp. 53-57
Author(s):  
T. N. Gavva ◽  
L. V. Kuzmenkova ◽  
Yu. N. Fedulaev ◽  
T. V. Pinchuk ◽  
D. D. Kaminer ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Clinical Case ◽  
Clinical Manifestations ◽  
Lung Damage ◽  
Newly Diagnosed ◽  
Systemic Lupus ◽  
Lung Lesions ◽  
Laboratory Parameters ◽  
Clinical Interest

A case of lung damage in systemic lupus erythematosus (SLE) in a 33-year-old woman is described. This case is of clinical interest due to the complexity of diagnosis due to the fact that SLE is a disease with diverse clinical manifestations involving many organs and systems, which often makes it difficult to timely recognize the onset of the disease. SLE still remains a challenge and requires special attention to the patient s history, clinical and laboratory parameters of the patient, as well as specific immunological examinations.

Sign in / Sign up

Export Citation Format

Share Document